Alzheimer's disease: Current treatment options and future developments; Focus on rivaroxaban: a novel oral factor Xa inhibitor to prevent stroke in nonvalvular atrial fibrillation
Coherus Announces Lowest Price for Humira Biosimilar, Partners with Mark Cuban Cost Plus
Coherus will launch Yusimry in July with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors); “the lowest price announced to date of any adalimumab offering in the United States,” the company said.
Bausch + Lomb Exec Discusses Novel Dry Eye Disease Treatment
Miebo is the first and only prescription eye drop approved for dry eye disease (DED) that directly targets tear evaporation.
FDA Accepts BLA for Lifileucel for Difficult-to-Treat Melanoma
Lifileucel is a polyclonal tumor infiltrating lymphocyte (TIL) therapy designed for patients with advanced melanoma who have experienced progression after previous treatment with anti-PD-1/L1 therapy and targeted therapy.
New Heart Failure Med Will be Priced 'Competitively'
Inpefa (sotagliflozin) is in the SGLT inhibitor class recommended as first-line treatment for heart failure by the American Heart Association and other groups. Jardiance (empaglifozin), a competitor in that class, has a list price of $570.48 for a month's supply.
Drug Manufacturer Coupons: Marketing Tools Perceived as Charitable Assistance
The frequency of drug manufacturer coupon utilization is associated with more market competition—but not patients’ out-of-pocket costs.
FDA Clears Paxlovid as First Oral Antiviral for COVID-19
More than 11.6 million treatment courses of the medication have been prescribed in the U.S. to date.
2 Clarke Drive Cranbury, NJ 08512